Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Raw Materials (2023 - 2024)

Historic Raw Materials for Tarsus Pharmaceuticals (TARS) over the last 2 years, with Q1 2024 value amounting to $2.5 million.

  • Tarsus Pharmaceuticals' Raw Materials changed N/A to $2.5 million in Q1 2024 from the same period last year, while for Mar 2024 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2023, which is N/A changed from last year.
  • As of Q1 2024, Tarsus Pharmaceuticals' Raw Materials stood at $2.5 million.
  • Tarsus Pharmaceuticals' Raw Materials' 5-year high stood at $2.5 million during Q4 2023, with a 5-year trough of $2.5 million in Q4 2023.